NewAmsterdam Pharma (NAMS) Change in Account Payables (2023 - 2026)

NewAmsterdam Pharma has disclosed Change in Account Payables across 4 years of filings, most recently posting -$793000.0 for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$793000.0, down 135.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 178.16% YoY), and the FY2025 annual result was $4.9 million, up 137.91% from the prior year.
• Change in Account Payables came in at -$793000.0 for Q1 2026 at NewAmsterdam Pharma, down from $5.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $12.9 million in Q4 2023 to a low of -$9.2 million in Q3 2023.
• The 4-year median for Change in Account Payables is -$793000.0 (2026), against an average of -$289384.6.
• Peak annual rise in Change in Account Payables reached 266.34% in 2025, while the deepest fall reached 219.11% in 2025.
• NewAmsterdam Pharma's Change in Account Payables stood at $12.9 million in 2023, then tumbled by 124.79% to -$3.2 million in 2024, then surged by 266.34% to $5.3 million in 2025, then plunged by 114.91% to -$793000.0 in 2026.
• The last three Change in Account Payables figures came in at -$793000.0 (Q1 2026), $5.3 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.